Recovery of function requires the regeneration and rewiring of neurons. The major factors limiting regrowth are extracellular inhibitors in CNS tissue called Nogo-A, MAG and OMgp. The company has developed a decoy receptor – called Nogo Trap - that binds the growth inhibitors allowing the body to grow nerve fibers naturally and directly targeting restoration across all facets of growth: axonal regeneration (long distance), axonal sprouting (medium distance) and synaptic plasticity.
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth. The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.
Manufacturing/Regulatory - The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1/2 trial in patients with chronic spinal cord injury.
Patents - The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use.
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth. The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.
Manufacturing/Regulatory - The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1/2 trial in patients with chronic spinal cord injury.
Patents - The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use.